-
-
-
-
-
-
-
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
-
-
-
-
-
-
-
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
-
-
-
-
-
-
-
BeiGene (BGNE) Announces China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
-
-
-
-
-
-
-
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
-
-
-
-
-
-
-
BeiGene (BGNE) Reports Inclusion in China National Reimbursement Drug List of Tislelizumab in Three New Indications, BRUKINSA in One New Indication, and the First Listing for Pamiparib
-
-
-
-
-
-
-
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
-
-
-
-
-
-
12,341 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All